Clinical trials: Breast Cancer/ Metastatic Breast Cancer
Advanced Breast Cancer, Metastatic Breast Cancer
"Curcumin" in Combination With Chemotherapy in Advanced Breast Cancer
The aim of this study is to assess benefits of treatment with intravenous Curcumin® (CUC-01) vs placebo, in combination with paclitaxel chemotherapy, and to estimate the risk of adverse events in patients with locally advanced…
- Trial name
- NCT03072992
- Testing
- Curcumin, Paclitaxel
- Where
- Armenia
- Volunteers
- 150 people
- Sponsor
- National Center of Oncology, Armenia
Breast Cancer
Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant, anastrozole, or exemestane may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount…
- Trial name
- SoFEA (NCT00253422)
- Testing
- Anastrozole, Exemestane, Fulvestrant
- Where
- 2 sites in United Kingdom
- Volunteers
- 698 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer
This study is designed to compare the safety and efficacy of JSKN003 versus T-DM1 in unrespectable locally advanced and/or metastatic HER2-positive breast cancer participants previously treated with trastuzumab and taxane.
- Trial name
- NCT06846437
- Testing
- JSKN003, Trastuzumab emtansine (T-DM1)
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Shanghai JMT-Bio Inc.
Breast Cancer, Lung Cancer
Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer
This is a multicenter, open-label, randomized, controlled study to test the hypothesis that ePRO monitoring added to usual care helps prolong OS or maintain and improve HRQoL in patients with unresectable advanced cancers or…
- Conditions
- Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer
- Trial name
- NCT05931445
- Testing
- e-PRO monitoring
- Where
- Japan
- Volunteers
- 500 people
- Sponsor
- Comprehensive Support Project for Oncology Research
Breast Cancer
SHR-A1811 and THPy in First or Second Line for HER2 Positive Advanced Breast Cancer Brain Metastases
The aim of this project is to evaluate whether the sequence of Trastuzumab，pyrotinib and Nab-Paclitaxel in first line followed by SHR-A1811 in second line is superior to the sequence of SHR-A1811 in first line followed by…
- Trial name
- NCT06975475
- Testing
- SHR-A1811,tratuzumab,pyrotinib,Nab-Paclitaxel
- Volunteers
- 60 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Breast Neoplasms
A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.
Assessment of safety and efficacy of SU11248 in patients with metastatic breast cancer who have failed selected other therapies.
- Trial name
- NCT00078000
- Testing
- SU011248
- Where
- 10 sites in United States
- Volunteers
- 64 people
- Sponsor
- Pfizer
Breast Cancer
Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer
This randomized phase II trial is studying metronomic low-dose cyclophosphamide and methotrexate to see how well they work compared to metronomic low-dose cyclophosphamide, methotrexate, and bevacizumab in treating women with…
- Trial name
- NCT00083031
- Testing
- bevacizumab, cyclophosphamide, methotrexate
- Where
- 4 sites in United States
- Volunteers
- 57 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Breast Cancer, Triple Negative Breast Cancer
Atezolizumab Plus CArboplatin Plus Nab-paclitaxel
Primary objective: To provide preliminary evidence on the efficacy of atezolizumab plus carboplatin plus paclitaxel as first-line therapy in metastatic triple-negative PD-L1 positive breast cancer patients as evaluated by %…
- Conditions
- Metastatic Breast Cancer, Triple Negative Breast Cancer, PD-L1 Gene Mutation
- Trial name
- NCT05266937
- Testing
- Atezolizumab,Paclitaxel, Carboplatin
- Where
- 15 sites in Italy
- Volunteers
- 49 people
- Sponsor
- Consorzio Oncotech
Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain
Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis
This phase I/Ib trial tests the safety, side effects, and best dose of vinorelbine when given in combination with trotabresib in treating patients with HER2 positive breast cancer that has spread to the central nervous system or…
- Conditions
- Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Leptomeninges
- Trial name
- NCT06137651
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- United States
- Sponsor
- Northwestern University
Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC)
Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer
To evaluate the clinical efficacy (objective response rate, ORR) of mass spectrometry-based absolute quantification-guided selection and matching of ADC/PDC therapy in patients with locally advanced or metastatic pancreatic…
- Trial name
- PROBE (NCT07825753)
- Testing
- Trastuzumab emtansine (T-DM1), Trastuzumab deruxtecan (T-DXd), Datopotamab deruxtecan (Dato-DXd)
- Where
- China
- Volunteers
- 225 people
- Sponsor
- Fudan University
Solid Tumor
A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
In phase Ia study, the safety and tolerability of SI-B003 in patients with recurrent or metastatic solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum…
- Trial name
- NCT04606472
- Testing
- SI-B003
- Where
- 8 sites in China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Metastatic Breast Cancer
Tesmilifene in Combination With Docetaxel in the Treatment of Metastatic Breast Cancer
This is a Phase II study designed to evaluate whether the co-administration of a fixed dose of tesmilifene and a standard regimen of docetaxel alters the plasma pharmacokinetics of docetaxel.
- Trial name
- NCT00364195
- Testing
- Tesmilifene (YMB1002)
- Where
- 3 sites in Serbia
- Volunteers
- 33 people
- Sponsor
- YM BioSciences
Metastatic Breast Cancer
MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer
This is a phase Ib trial that evaluates the safety and tolerability of MK-2206 given in combination with exemestane +/- goserelin in pre- and post-menopausal patients with hormone receptor-positive metastatic breast cancer.
- Trial name
- NCT01240928
- Testing
- MSK-2206, Exemestane, Goserelin
- Sponsor
- Vanderbilt-Ingram Cancer Center
Locally Advanced Breast Cancer, Metastatic Breast Cancer
A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
The main purpose of this study is to evaluate the effectiveness of inavolisib based regimen in participants with endocrine-resistant, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA)-mutated…
- Trial name
- reaINAVO (NCT07347600)
- Testing
- Inavolisib, Palbociclib, Fulvestrant
- Where
- 32 sites in China
- Volunteers
- 500 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasms, Breast Cancer
Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer
This clinical study is designed as an open, single group, multi-center, phase 4 clinical study to assess the safety of eribulin which is approved for the treatment of the patients in Korea with locally advanced or metastatic…
- Trial name
- ESKIMO (NCT01961544)
- Testing
- Eribulin mesylate
- Where
- 14 sites in South Korea
- Volunteers
- 101 people
- Sponsor
- Eisai Korea Inc.
Breast Cancer
Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)
Single agent endocrine therapy (ET), with selective estrogen receptor degraders (SERDs; i.e. fulvestrant or elacestrant), is an option for patients with pre-treated hormone receptor-positive (HR+) breast cancer (BC) with indolent…
- Trial name
- COMBINE-01 (NCT07395336)
- Testing
- elacestrant and exemestane
- Where
- Italy
- Volunteers
- 26 people
- Sponsor
- European Institute of Oncology
Recurrent Breast Cancer, Stage IV Breast Cancer
Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer
Sorafenib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Estradiol can cause the growth of breast cancer.
- Trial name
- NCT00217399
- Testing
- sorafenib tosylate, anastrozole
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
HER2 Positive Metastatic Breast Cancer
A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab
Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors. This study is a randomized, multi-center, multinational, open-label, active-controlled, parallel design study of the combination of…
- Trial name
- NCT02422199
- Testing
- pyrotinib, Lapatinib, capecitabine
- Where
- 2 sites in China
- Volunteers
- 128 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Metastatic Breast Cancer
Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention
This trial will evaluate the SHARE-MC educational intervention designed to address sexual health needs and related adjustment in women with metastatic breast cancer.
- Trial name
- SHARE-MC (NCT07519200)
- Testing
- SHARE-MC, Informational Booklet
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Bevacizumab and Doxorubicin Hydrochloride Liposome in Treating Women With Locally Recurrent or Metastatic Breast Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00445406
- Testing
- bevacizumab + doxorubin hydrochloride liposme, Bevacizumab
- Where
- Switzerland
- Volunteers
- 43 people
- Sponsor
- Swiss Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.